Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | MPO | P05164 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.36 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.35 |
| ▸ | PER2 | O15055 | 1/20 | 0.35 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.35 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1512139 | 0.81 | ADRA1D (0.40) | ADRA1DADRA1AADRA1BMPOSLC6A4 | |
| SCHEMBL2552728 | 0.81 | CA2 (0.41) | CA2 | |
| SCHEMBL27786995 | 0.80 | ADRA1D (0.39) | ADRA1DADRA1AADRA1BSLC6A4PTGS2 | |
| SCHEMBL13180014 | 0.79 | KDM4E (0.42) | ADRA1DADRA1AADRA1BSLC6A4PTGS2 | |
| SCHEMBL1151001 | 0.77 | ADRA1D (0.40) | ADRA1DADRA1AADRA1BSLC6A4PTGS2 | |
| SCHEMBL5124506 | 0.76 | MAOA (0.39) | ADRA1DADRA1AADRA1BMPOSLC6A4 | |
| SCHEMBL4012771 | 0.76 | ADRA1D (0.39) | ADRA1DADRA1AADRA1BSLC6A4PTGS2 | |
| SCHEMBL5663968 | 0.76 | ADRA1D (0.41) | CA2ADRA1DADRA1AADRA1BESR2 | |
| SCHEMBL1151151 | 0.76 | CA12 (0.43) | CA2ADRA1DADRA1AADRA1BDDR1 | |
| Hydrochloric Acid SCHEMBL1017408 | 0.75 | MAOA (0.40) | ADRA1DADRA1AADRA1BMPOSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2291377-B1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | AVEXA LTD (AU) | 2015-02-18 | — | — | EP | disclosed |
| US-8431581-B2 | Imidazopyrimidines and uses thereof | AVEXA LIMITED (AU) | 2013-04-30 | — | — | US | disclosed |
| US-8431581-B2 | Imidazopyrimidines and uses thereof | AVEXA LIMITED (AU) | 2013-04-30 | — | — | US | disclosed |
| US-8431581-B2 | Imidazopyrimidines and uses thereof | AVEXA LIMITED (AU) | 2013-04-30 | — | — | US | disclosed |
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-02-03 | — | — | US | disclosed |
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-02-03 | — | — | US | disclosed |
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-02-03 | — | — | US | disclosed |
| WO-2010000031-A1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | TPMT, DPYD, IMPDH1 | CA2 1554/4885ADRA1D 2810/4885ADRA1A 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.